Two independent approaches reported by researchers at Albert Einstein College of Medicine aim to solve CAR‑T cell persistence. One Science Advances paper described a modular protein scaffold (HCW9206) that links IL‑7, IL‑15 and IL‑21 to generate CAR‑T products enriched for long-lived T memory stem cells, producing durable disease control in mouse models of blood cancer and suppression of HIV reservoirs. A complementary report detailed a multi‑cytokine fusion scaffold manufacturing strategy that increased the frequency of self‑renewing T memory stem cells and prolonged antitumor activity in preclinical studies. Both teams argue that enhancing intrinsic survival and self‑renewal pathways during ex vivo manufacture can reduce relapse rates and broaden CAR‑T applicability. Translation will require clinical-scale manufacturing validation and safety assessments of sustained cytokine exposure.